中文 | ENG

第58卷 第3期 2025-5
Elevating the standards of scientific editing in clinical surgery: Learning from editorial and journal role models

.........................

第58卷 第3期 2025-5
Improving online physician evaluations for surgeons using sentiment analysis and alternative perspectives

.........................

第58卷 第3期 2025-5
Ensuring ethical and qualified authorship: The key to trustworthiness in clinical surgery journal

.........................

第58卷 第3期 2025-5
Artificial intelligence for academic purpose in clinic surgery: ChatGPT, Turnitin, and false positive

.........................

第58卷 第3期 2025-5
COVID-19, COVID-19 vaccination, risk of cardiac myxoma in view of clinical surgery

.........................

第58卷 第3期 2025-5
Eggplant deformity in penile fracture

.........................

第58卷 第3期 2025-5
Splenectomy for Klippel-Trenaunay syndrome: Systematic review and case series

.........................

第58卷 第3期 2025-5
Comments on “Risk factors for spinal cord injury without radiographic abnormality in trauma cases at a single trauma center”

.........................

第58卷 第3期 2025-5
Impact of fluorescence-guided surgery on splenic preservation: A case of splenic hydatidosis

.........................

第58卷 第3期 2025-5
Adult pancreatoblastoma presentingwith obstructive jaundice: A case report and literature review

.........................

第58卷 第3期 2025-5
Pilonidal disease management in young adults: A retrospective analysis of practices in a single tertiary center in Bahrain

.........................

第58卷 第3期 2025-5
Long-term comparative outcomes in patients undergoing transcatheter aortic valve implantation with self-expanding valves versus balloon-expandable valves: A retrospective observational study

.........................

第58卷 第3期 2025-5
Comparative study between the effectiveness of Amnion-CollaGee (Collagen-Gelatin-Elastin) as a biological product wound dressing and conventional dressing on the donor site of the split-thickness skin graft in animals model (rats)

.........................

第58卷 第3期 2025-5
Enhancing mortality Probability Model II predictive accuracy with the lethal triad in intensive care unit trauma patients: A retrospective study

.........................

第58卷 第3期 2025-5
Dr. Shao-Wei Chen's contribution to analysis of outcomes of patients undergoing cardiac surgery and aortic disease: Big data analytics

.........................

第58卷 第2期 2025-3
Predatory publisher and low standard journal: An emerging problem in clinical surgery field

.........................

第58卷 第2期 2025-3
Conflict of interest in clinical surgery: Contemporary concern in digital era

.........................

第58卷 第2期 2025-3
Postpublication redecision and pitfalls of inadequate standards in scientific surgical journals: Important consideration in academic publication

.........................

第58卷 第2期 2025-3
Spontaneous bilateral basal ganglia hemorrhage

.........................

第58卷 第2期 2025-3
Academic characterization of the Formosan Journal of Surgery: A five-year bibliometric analysis

.........................
登入帳號才能閱讀全文
 
篇名 Pressurized intraperitoneal aerosol chemotherapy (PIPAC): Why it will transform cancer surgery
作者 Marc Andre Reymond, Yaroslv Sautkin, Hans Schönfelder, Wiebke Solass
卷期/出版年月 57卷6期 (2024/11)
頁次 225-231
摘要 Pressurized intraperitoneal aerosol chemotherapy (PIPAC) represents an innovative method for delivering chemotherapy directly into the abdominal cavity, offering a targeted, effective, and less toxic treatment option for patients with nonresectable peritonealmetastasis (PM). PIPAC is increasingly adopted due to its benefits over traditional therapies, including enhanced drug penetration, reduced systemic toxicity, and improved efficacy in chemoresistant PM. Performed laparoscopically, PIPAC is minimally invasive, often outpatient, and well-tolerated, preserving patients’ quality of life. So far, PIPAC has been mainly used in advanced PM from ovarian, gastric, and colorectal cancers, where it can be effective even after other treatments have failed. The repeatable nature of PIPAC offers opportunities for maintenance therapy and long-term disease control. A recent meta-analysis of PIPAC studies reported a 4% nonaccess rate and 39% of patients completing three or more cycles, with only 4%experiencing severe toxicities. Pathological responses were observed in 68% of cases, indicating reliable efficacy. A first randomized trial showed PIPAC’s superiority in objective response rates and quality of life comparedwith intravenous chemotherapy for platinum-resistant ovarian cancer. Research in PIPAC is dynamic and multidisciplinary, aiming to refine the technique, minimize side effects, and expand its applicability to various cancers. Studies focus on the efficacy of aerosolized drug delivery, including nanoparticles and RNAbased therapies, which offer targeted treatment options with promising therapeutic potential. Innovations such as electrostatic precipitation PIPAC (ePIPAC) combine enhanced drug distribution with increased tissue penetration, representing significant advancements in PM treatment. Future developments will focus on optimizing aerosol characteristics, drug formulations, and personalized medicine approaches.
關鍵詞 PIPAC; Peritoneum; Tumor regression; PRGS; Drug device; Chemotherapy
分類 Review Article

台灣外科醫學會雜誌 © 2006 Taiwan Surgical Association All Rights Reserved
會 址:台北市南京東路五段 31 號 3 樓
電 話:(02) 2769-7845 傳 真:(02) 2746-7149 Email: journal@surgery.org.tw